OBJECTIVE: To identify biomarkers that distinguish between active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and remission in a manner superior or complementary to established markers of systemic inflammation. METHODS: Markers of vascular injury and angiogenesis were measured before and after treatment in a large clinical trial in AAV: 163 subjects enrolled in the Rituximab in ANCA-Associated Vasculitis trial were screened for the present study. Serum levels of E-selectin, intercellular adhesion molecule 3 matrix metalloproteinase protein 1 (MMP-1), MMP-3, MMP-9, P-selectin, thrombomodulin, and vascular endothelial growth factor were measured at study screening (time of active disease) and at month 6. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels had been measured at the time of the clinical visit. The primary outcome measure was the difference in marker level between screening and month 6 among patients whose disease was in remission (Birmingham Vasculitis Activity Score for Wegener's granulomatosis [BVAS/WG] score of 0) at month 6. RESULTS: All patients had severe active vasculitis at screening (mean ± SD BVAS/WG score 8.6 ± 3.2). Among the 123 patients whose disease was clinically in remission at month 6, levels of all markers except E-selectin showed significant declines. MMP-3 levels were also higher among the 23 patients with active disease at month 6 than among the 123 patients whose disease was in remission. MMP-3 levels correlated weakly with ESR and CRP levels. CONCLUSION: Many markers of vascular injury and angiogenesis are elevated in severe active AAV and decline with treatment, but MMP-3 appears to distinguish active AAV from remission better than the other markers studied. Further study of MMP-3 is warranted to determine its clinical utility in combination with conventional markers of inflammation and ANCA titers.
RCT Entities:
OBJECTIVE: To identify biomarkers that distinguish between active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and remission in a manner superior or complementary to established markers of systemic inflammation. METHODS: Markers of vascular injury and angiogenesis were measured before and after treatment in a large clinical trial in AAV: 163 subjects enrolled in the Rituximab in ANCA-Associated Vasculitis trial were screened for the present study. Serum levels of E-selectin, intercellular adhesion molecule 3 matrix metalloproteinase protein 1 (MMP-1), MMP-3, MMP-9, P-selectin, thrombomodulin, and vascular endothelial growth factor were measured at study screening (time of active disease) and at month 6. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels had been measured at the time of the clinical visit. The primary outcome measure was the difference in marker level between screening and month 6 among patients whose disease was in remission (Birmingham Vasculitis Activity Score for Wegener's granulomatosis [BVAS/WG] score of 0) at month 6. RESULTS: All patients had severe active vasculitis at screening (mean ± SD BVAS/WG score 8.6 ± 3.2). Among the 123 patients whose disease was clinically in remission at month 6, levels of all markers except E-selectin showed significant declines. MMP-3 levels were also higher among the 23 patients with active disease at month 6 than among the 123 patients whose disease was in remission. MMP-3 levels correlated weakly with ESR and CRP levels. CONCLUSION: Many markers of vascular injury and angiogenesis are elevated in severe active AAV and decline with treatment, but MMP-3 appears to distinguish active AAV from remission better than the other markers studied. Further study of MMP-3 is warranted to determine its clinical utility in combination with conventional markers of inflammation and ANCA titers.
Authors: J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani Journal: Arthritis Rheum Date: 2001-04
Authors: C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise Journal: Ann Rheum Dis Date: 2002-02 Impact factor: 19.103
Authors: S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston Journal: Ann Rheum Dis Date: 2001-09 Impact factor: 19.103
Authors: M M Boomsma; C A Stegeman; M J van der Leij; W Oost; J Hermans; C G Kallenberg; P C Limburg; J W Tervaert Journal: Arthritis Rheum Date: 2000-09
Authors: Anne Ponthieux; Bernard Herbeth; Suzanne Droesch; Nadia Haddy; Daniel Lambert; Sophie Visvikis Journal: Atherosclerosis Date: 2004-02 Impact factor: 5.162
Authors: Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel Journal: Ann Rheum Dis Date: 2012-09-12 Impact factor: 19.103
Authors: Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman Journal: Clin J Am Soc Nephrol Date: 2013-01-04 Impact factor: 8.237
Authors: Mira Choi; Adrian Schreiber; Claudia Eulenberg-Gustavus; Claus Scheidereit; Jan Kamps; Ralph Kettritz Journal: J Am Soc Nephrol Date: 2017-07-07 Impact factor: 10.121
Authors: Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell Schroeder; Brian Kabat; Carol A Langford; Gary S Hoffman; Fernanado C Fervenza; Cees G M Kallenberg; Philip Seo; Robert Spiera; E William St Clair; Paul Brunetta; John H Stone; Peter A Merkel; Ulrich Specks; Paul A Monach Journal: Arthritis Rheumatol Date: 2018-05-07 Impact factor: 10.995
Authors: Stephen W Olson; David Owshalimpur; Christina M Yuan; Charles Arbogast; Thomas P Baker; David Oliver; Kevin C Abbott Journal: Clin J Am Soc Nephrol Date: 2013-05-02 Impact factor: 8.237
Authors: Sung Soo Ahn; Taejun Yoon; Yong-Beom Park; Maria Prendecki; Gurjeet Bhangal; Stephen P McAdoo; Sang-Won Lee Journal: Arthritis Res Ther Date: 2021-03-08 Impact factor: 5.156